Profile data is unavailable for this security.
About the company
4basebio PLC is a United Kingdom-based biotechnology company. The Company is focused on life sciences and in particular the development of synthetic Deoxyribonucleic acid (DNA) and nanoparticles suitable for inclusion in, or delivery of, therapeutic payloads for cell and gene therapies and vaccines. It is engaged in the development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads in patients. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications.
- Revenue in GBP (TTM)596.00k
- Net income in GBP-9.84m
- Incorporated2020
- Employees--
- Location4Basebio PLC25 Norman Way, OverCAMBRIDGE CB24 5QEUnited KingdomGBR
- Phone+44 122 396 7943
- Websitehttps://www.4basebio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 36.26m | 11.00 | -- | 8.28 | -- | 224.34 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| Poolbeg Pharma PLC | 0.00 | -4.38m | 38.00m | 8.00 | -- | 3.05 | -- | -- | -0.0088 | -0.0088 | 0.00 | 0.0249 | 0.00 | -- | -- | 0.00 | -29.11 | -- | -30.18 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.11 | -- | -- | -- |
| Futura Medical PLC | 8.40m | -3.75m | 100.75m | 12.00 | -- | 12.82 | -- | 12.00 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Scancell Holdings Plc | 0.00 | -5.86m | 134.79m | 61.00 | -- | -- | -- | -- | -0.0068 | -0.0068 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -23.24 | -31.66 | -32.48 | -37.66 | -- | -- | -- | -822.37 | -- | -- | 1.21 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.30m | 148.85m | 34.00 | -- | 129.72 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.011 | 0.00 | -- | -- | 0.00 | -130.90 | -213.06 | -443.92 | -963.12 | -- | -- | -- | -- | -- | -5.99 | 0.9022 | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| hVIVO PLC | 64.38m | 17.45m | 155.81m | 274.00 | 9.07 | 4.05 | 7.54 | 2.42 | 0.0252 | 0.0252 | 0.0932 | 0.0565 | 0.9242 | -- | 4.25 | 234,974.50 | 25.04 | -0.643 | 46.68 | -1.29 | -- | -- | 27.10 | -0.765 | 1.60 | -- | 0.2530 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| 4Basebio PLC | 596.00k | -9.84m | 166.54m | -- | -- | -- | -- | 279.43 | -0.7843 | -0.7843 | 0.0476 | -0.4075 | 0.0508 | 0.6453 | 10.64 | -- | -83.78 | -- | -97.43 | -- | 69.63 | -- | -1,650.67 | -- | 2.53 | -18.44 | 1.51 | -- | 88.81 | -- | -48.83 | -- | -- | -- |
| Avacta Group Plc | 22.62m | -25.89m | 171.73m | 154.00 | -- | 3.49 | -- | 7.59 | -0.0867 | -0.0867 | 0.075 | 0.1334 | 0.2555 | 4.63 | 3.15 | 146,876.60 | -29.24 | -- | -61.16 | -- | 42.08 | -- | -114.45 | -- | 1.21 | -1.23 | 0.3875 | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| Bioventix PLC | 13.61m | 8.10m | 193.65m | 17.00 | 24.27 | 16.13 | 23.59 | 14.23 | 1.53 | 1.53 | 2.57 | 2.30 | 1.01 | 1.57 | 2.26 | 800,387.60 | 59.95 | 58.33 | 67.24 | 63.62 | 93.20 | 93.09 | 59.51 | 64.12 | 7.07 | -- | 0.00 | 90.92 | 6.17 | 7.93 | -3.29 | 6.67 | -28.40 | 16.25 |
| Allergy Therapeutics plc | 55.20m | -40.22m | 247.85m | 635.00 | -- | 66.96 | -- | 4.49 | -0.0107 | -0.0107 | 0.0137 | 0.0008 | 0.8389 | 2.09 | 7.40 | -- | -61.12 | -22.88 | -86.97 | -30.15 | 53.87 | 66.47 | -72.86 | -24.88 | 1.01 | -8.70 | 0.8931 | -- | -7.36 | -5.62 | 6.63 | -- | 1.88 | -- |
| Puretech Health PLC | 371.84k | -65.52m | 389.83m | 90.00 | -- | 1.55 | -- | 1,048.39 | -0.239 | -0.239 | 0.0014 | 1.05 | 0.0007 | -- | 0.2252 | 4,131.56 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Oxford BioMedica plc | 97.28m | -142.02m | 436.93m | 834.00 | -- | 6.56 | -- | 4.49 | -1.44 | -1.44 | 0.9642 | 0.6292 | 0.3012 | 4.09 | 4.21 | 136,252.10 | -51.98 | -19.60 | -66.85 | -24.68 | 36.74 | 50.74 | -172.59 | -44.38 | 2.07 | -12.47 | 0.6077 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Holder | Shares | % Held |
|---|---|---|
| M&G Investment Management Ltd.as of 12 Nov 2024 | 4.63m | 36.12% |
| Aramea Asset Management AGas of 30 Jun 2022 | 143.33k | 1.12% |
| Deutsche Bank AG (Private Banking Germany)as of 30 Sep 2024 | 51.67k | 0.40% |
| DWS Investment GmbHas of 30 Aug 2024 | 13.36k | 0.10% |
